Shanghai OPM Biosciences Co., Ltd. Class A
SSSE:68829356.61
CNY
-2.51
(-4.25%)
ISIN
CNE100005PF1
Return %
Stock
S&P 500
1Y
2.57
14.20
3Y
16.58
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhi Hua Xiao
- Full Time Employees
- 367
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Shanghai China
- IPO Date
- Sep 2, 2022
- Website
- opmbiosciences.com
- Similar Companies
- Business
- Shanghai OPM Biosciences Co., Ltd. is a biotechnology company that specializes in the research, development, manufacturing, and commercialization of cell culture media products and provides comprehensive contract development and manufacturing organization (CDMO) services for the global biopharmaceutical industry. Founded in 2013 and headquartered in Shanghai, China, the company serves biopharmaceutical developers, contract research organizations, and academic institutions across the Asia-Pacific region, North America, and Europe. The company operates through two core business segments: Cell Culture Media and Biologics CDMO Services. Its cell culture media portfolio consists of chemically defined, animal origin-free, and serum-free basal media and feed formulations engineered for Chinese Hamster Ovary (CHO) cell lines, human embryonic kidney 293 (HEK293) cells, hybridoma cells, insect cells, and viral packaging hosts utilized in the manufacturing of monoclonal antibodies, bispecific antibodies, recombinant proteins, viral vaccines, and cell and gene therapies; customized media formulation development and optimization; and industrial-scale dry powder and liquid media production manufactured under current Good Manufacturing Practice (cGMP) standards. Its CDMO business, supported by its subsidiary operations including SureGen Biologics, delivers integrated end-to-end development and manufacturing solutions comprising high-expression stable cell line development; upstream and downstream bioprocess development and scale-up; analytical method development, qualification, and structural characterization; formulation development; cGMP clinical trial material manufacturing for Investigational New Drug (IND) filings; commercial-scale manufacturing; and regulatory dossier preparation for global regulatory authorities such as the NMPA, US FDA, and EMA. In recent developments following its public listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, Shanghai OPM Biosciences Co., Ltd. has expanded its production footprint through the operational scale-up of automated, large-scale media production facilities and the addition of commercial-scale single-use bioreactor capacity to support growing biologics CDMO demand. The company has also accelerated its internationalization strategy by expanding overseas operational entities, including OPM Biosciences (USA) Inc., establishing global logistics and technical support channels, forging strategic supply agreements and research collaborations with multinational biopharmaceutical firms for customized cell culture media, and launching specialized chemically defined media platforms targeted at viral vector production for advanced cell and gene therapies.